Bloomberg Businessweek Daily: Apple Growth Decelerates (Podcast)

Apple’s September-quarter sales growth decelerated from 16% in the June quarter, and China revenue missed estimates; this was its first earnings report since John Ternus took over as CEO. Separately, Anthropic disclosed a twelve-fold increase in quarterly revenue and plans to spend over $895 billion in the coming years. Marvell agreed to buy Lumentum in a reported $115 billion deal.

Analysis

Apple’s China miss matters less as a single-quarter estimate miss than as a test of whether its upgrade cycle can offset mature-market saturation. If China weakness persists, operating leverage and the premium multiple—not just unit growth—become vulnerable; a rebound in the next quarter or resilient monetization would invalidate that read. The CEO transition adds execution risk, but one report is not enough to attribute the slowdown to leadership.

Anthropic’s reported revenue acceleration supports continued demand for AI compute, but the spending figure is not investable without its period, committed-versus-planned split, funding source, and supplier allocation. If it reflects durable contracted capacity, the benefit broadens beyond model developers to networking and optical infrastructure; if spending outruns monetization, the same buildout creates cancellation and utilization risk for the supply chain.

The Marvell–Lumentum transaction may consolidate exposure to AI data-center connectivity, but headline deal size alone says little about value creation. Consideration, financing, closing conditions, and achievable integration savings determine whether MRVL gains strategic scale or assumes execution and balance-sheet risk. Near term, deal terms and regulatory review are the catalysts; over 6–18 months, customer qualification and realized cross-selling matter. No price, terms, or detailed guidance are provided, so avoid treating the announcement as proof of accretion.

Key Decisions for Investors

• AAPL: avoid chasing a post-earnings bounce; consider relative underweight versus diversified mega-cap tech only if management commentary or the next report confirms China weakness and decelerating growth. Falsifier: stabilization in China demand alongside resilient guidance or monetization.
• ANT / AI infrastructure: keep exposure sized to verified contracts, not headline spending intentions. Track the spending horizon, funding commitments, and supplier disclosures; a material reduction in planned capacity or weaker utilization would challenge the AI-infrastructure thesis.
• MRVL–LITE: do not trade the deal headline as a standalone long-MRVL signal. Reassess after terms, financing, regulatory path, and pro forma leverage are disclosed; financing strain, a prolonged review, or weak integration economics would be downside catalysts.
• Near-term risk control: absent share-price reactions and detailed company guidance, there is no well-grounded entry level or compelling options setup in the supplied information.